phase i dose escalation of imc-f106c - first prame × cd3 immtac bispecific protein in solid tumors
Published 2 years ago • 164 plays • Length 2:43
Download video MP4
Download video MP3
Similar videos
-
7:44
ash23: abbv-383 bcma x cd3 bispecific antibody for relapsed/refractory myeloma | ravi vij, md, mba
-
1:29
bispecific bcma-cd3 antibody teclistamab is efficacious and tolerable in r/r mm
-
1:52
phase i trial of bi 764532, a t-cell engager for dll3-positive nec and sclc
-
3:30
sc vs. iv administration of a bcma-cd3 bispecific antibody for r/r myeloma
-
1:08
bretuximab vedotin plus re-induction chemotherapy for cd30 r/r aml
-
1:59
tangible benefit for flt3-itd r/r aml on quizartinib
-
4:54
acc 2019: odyssey outcomes trial - prof vera bittner
-
23:33
mindray hematologi bc-3200 baground abnormal
-
13:56
hematologi mindray bc-3600 error hgb failure,hgb**** #mindraybc3600#bagroundabnormal#hgberror
-
6:39
sar'579, a trifunctional anti-cd123 nk cell engager, in r/r aml, b-all, and hr-mds
-
5:28
regn5459, a bcma×cd3 bispecific antibody, in r/r multiple myeloma
-
2:20
farmaci neurologici
-
1:55
outcomes and options for r/r aml patients who fail venetoclax-based salvage therapy
-
2:43
case 3: low- to intermediate- risk essential thrombocythemia
-
1:21
cd20/cd3 bispecific antibodies in r/r dlbcl: glofitamab and epcoritamab
-
2:50
aurelia: phase 3 trial of bevacizumab combined with chemotherapy for ovarian cancer
-
1:11:57
nuclear cases for frcr
-
9:57
teclistamab, a bcma × cd3 bispecific antibody, in pts with rrmm: updated phase 1 results
-
7:18
response rate on phase 1/2 trial regn5458 (bcmaxcd3 bispecific antibody) for rrmm patients
-
2:49
results from the phase iii echo trial of acalabrutinib plus br in mcl
-
2:58
bcma 2 1 t-cell engager cc-93269 in patients with r/r myeloma
Clip.africa.com - Privacy-policy